Milestone Pharmaceuticals has announced the appointment of Joseph G. Oliveto as President and CEO. Oliveto, who was most recently CEO of Galleon Pharmaceuticals and previously served as President and CEO of Chelsea Therapeutics, is replacing company founder Phillippe Douville, who is now Chief Scientific Officer.
Milestone’s lead candidate, etripamil is an intranasal calcium channel antagonist in development for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Oliveto said, “As a later stage asset with an established mechanism of action, etripamil has the potential to fulfill an important unmet medical need for patients who suffer from PSVT. With our focused strategy, there is an opportunity to rapidly advance etripamil through the clinic and bring a much needed self-administered PSVT treatment to patients. I look forward to leading Milestone at this important juncture, to joining the strong development team and to the presentation of the exciting clinical study results at an upcoming scientific meeting.”
Milestone Chairman Paul F. Truex commented, “Joe’s late stage development and commercialization experience combined with his track record of successful strategic transactions is a great fit for Milestone as we plan to enter Phase 3 development for etripamil. We thank Philippe for his founding vision and leadership that brought us to this important transition point. We look forward to his continued contributions as Chief Scientific Officer.”
Read the Milestone Pharmaceuticals press release.
